Health Care & Life Sciences » Biotechnology | Audentes Therapeutics Inc.

Audentes Therapeutics Inc. | Ownership

Companies that own Audentes Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
4,331,844
11.61%
-675,223
0.02%
06/30/2018
Wellington Management Co. LLP
3,343,727
8.96%
-816,241
0.02%
06/30/2018
OrbiMed Advisors LLC
2,615,000
7.01%
-907,100
0.99%
06/30/2018
T. Rowe Price Associates, Inc.
2,336,304
6.26%
526,216
0.01%
06/30/2018
BlackRock Fund Advisors
2,282,390
6.11%
419,231
0%
06/30/2018
Redmile Group LLC
2,228,656
5.97%
920,130
2.5%
06/30/2018
SSgA Funds Management, Inc.
1,309,504
3.51%
314,734
0%
06/30/2018
The Vanguard Group, Inc.
1,257,242
3.37%
121,884
0%
06/30/2018
Deerfield Management Company LP
1,048,430
2.81%
-336,040
1.09%
06/30/2018
Jennison Associates LLC
1,020,556
2.73%
17,877
0.03%
06/30/2018

About Audentes Therapeutics

View Profile
Address
600 California Street
San Francisco California 94108
United States
Employees -
Website http://www.audentestx.com
Updated 07/08/2019
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.